预约演示
更新于：2026-08-12
Dexamethasone Sodium Phosphate
地塞米松磷酸钠
更新于：2026-08-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1959-08-26) |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-FCJDYXGNSA-N |
CAS号2392-39-4 |
关联
3,009
项与 地塞米松磷酸钠 相关的临床试验NCT07605416
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for improving overall survival of patients with plasma cell leukemia. Consolidation therapy is treatment given after initial therapy to kill any cancer cells that may remain in the body. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Carfilzomib inhibits protein complexes called proteasomes, which inhibits cancer cell growth and leads to cancer cell death. Lenalidomide may help kill cancer cells and prevents the growth of blood vessels that cancer cells need to survive. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Teclistamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving teclistamab as consolidation therapy after induction and autologous hematopoietic stem cell transplant may improve survival outcomes in patients with plasma cell leukemia, compared to standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone.
开始日期2027-04-20 |
申办/合作机构 |
NCT06437054
Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)
This study is a prospective, randomized pilot study. To verify an efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.
开始日期2026-12-15 |
NCT04366115
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.
开始日期2026-12-01 |
申办/合作机构 |
100 项与 地塞米松磷酸钠 相关的临床结果
登录后查看更多信息
100 项与 地塞米松磷酸钠 相关的转化医学
登录后查看更多信息
100 项与 地塞米松磷酸钠 相关的专利（医药）
登录后查看更多信息
1,514
项与 地塞米松磷酸钠 相关的文献（医药）2026-07-01·EUROPEAN JOURNAL OF NEUROLOGY
Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia‐Telangiectasia: A Systematic Review
Review
作者: Pisani, Francesco ; Spagnoli, Carlotta ; Paparella, Roberto ; Leuzzi, Vincenzo ; Urciuolo, Giorgia ; Panvino, Fabiola ; Galosi, Serena
ABSTRACT:
Introduction:
Ataxia‐telangiectasia (AT) is characterized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency, and increased cancer susceptibility. No disease‐modifying treatment is available. This systematic review aimed to evaluate the efficacy and safety of pharmacological interventions for ataxia in pediatric AT.
Method:
A systematic search was conducted across MEDLINE, Scopus, Web of Science, and
ClinicalTrials.gov
through December 2025. Eligible studies included randomized controlled trials (RCTs) and single‐arm interventional studies evaluating pharmacological treatments for cerebellar ataxia in patients aged ≤ 18 years with genetically confirmed AT.
Results:
Thirteen studies (3 RCTs, 10 single‐arm trials) involving 314 participants (mean age 10.87 years) were included. Interventions included betamethasone, erythrocyte‐encapsulated dexamethasone (eDSP), nicotinamide riboside (NR), leucine derivatives, and amantadine. Betamethasone demonstrated transient improvements in the Scale for the Assessment and Rating of Ataxia (SARA) and International Cooperative Ataxia Rating Scale (ICARS) scores, with dose‐dependent systemic toxicity. eDSP showed favorable tolerability but was ineffective in phase 3 trials, although subgroup analyses suggested a potential benefit in children aged 6–9 years. NR supplementation improved SARA and AT Neurological Examination Scale Toolkit (AT‐NEST) scores in open‐label studies. Leucine derivatives showed mixed results. Amantadine showed benefits in patients with extrapyramidal symptoms.
Conclusions:
The recurrent pattern of promising open‐label findings followed by negative phase 3 results highlights a translational gap attributable to methodological limitations, including small sample sizes, heterogeneous populations, and variable outcome measures. The non‐linear disease progression and age‐dependent treatment response further complicate trial design. Current evidence remains insufficient to guide clinical practice.
Trial Registration:
PROSPERO number: CRD420251184721
2026-07-01·VETERINARY ANAESTHESIA AND ANALGESIA
Novel ultrasound-guided flags assisted WalKing block for enhanced recovery after surgery (FAWKES) in three dogs undergoing tibial plateau levelling osteotomy
Article
作者: Le, Stephanie ; Gingold, Benjamin Mc ; Milloway, Matthew C
This case series describes a novel, regional anesthesia technique in three dogs of various breeds, aged 2.5, 8, and 10 years old, weighing 42.6, 32.6, and 13.4 kg, respectively, presenting for tibial plateau levelling osteotomy. Physical examination was unremarkable aside from evidence of a ruptured cranial cruciate ligament. After anesthetic premedication and induction of general anesthesia, the affected limb was aseptically prepared. A combination of regional nerve blocks was performed, including the inFiLtrating Around Genicular Structures (FLAGS) block, saphenous block, and periarticular knee infiltration; together, termed the Flags Assisted WalKing block for Enhanced recovery after Surgery (FAWKES). A mixture of 0.5% ropivacaine (4 mg kg-1), dexmedetomidine (1.6 ug kg-1), dexamethasone sodium phosphate (0.004 mg kg-1), and epinephrine (4 ug kg-1) was used for the FLAGS (0.2 mL kg-1), saphenous (0.1 mL kg-1), and periarticular knee infiltration (0.125 mL kg-1 per site; four sites). There were no increases in heart rate, respiratory rate, or mean arterial blood pressure greater than 20% from surgical start time to end time, aside from expected elevations following administration of anticholinergics or vasopressors. All dogs retained motor function postoperatively. Two of the three dogs ambulated on the operated limb within one hour of recovery. The third was nonweight-bearing but able to flex the stifle and elevate the limb. One dog was given a single postoperative dose of intravenous methadone (0.2 mg kg-1) 12 hours after surgery, whereas the remaining dogs required no rescue analgesia. All dogs ate within 12 hours of surgery and were discharged without complications. These findings suggest that the described multimodal analgesic plan, including the FAWKES block, provided adequate intraoperative analgesia while preserving motor function postoperatively. Controlled studies are required to evaluate the efficacy and safety of the FAWKES block, along with more detailed anatomical investigations of the canine stifle joint.
2026-06-01·AMERICAN JOURNAL OF VETERINARY RESEARCH
Repeated intravenous dexamethasone administration causes transient changes in leukocyte parameters in healthy warmblood horses
Article
作者: Vendrig, Johannes C. ; Roelfsema, Ellen ; Hendrikx, Anne L. ; Gehring, Ronette ; van Alphen, Jennifer ; van den Boom, Robin ; Teske, Erik ; Vernooij, Johannes C. M.
Abstract:
Objective:
To determine the effect of repeated IV administration of dexamethasone (0.06 mg/kg, q 24 h, twice) on WBC parameters in healthy adult horses.
Methods:
This prospective, longitudinal study was conducted from October 7 through November 5, 2024. Five warmblood mares received an IV dexamethasone sodium phosphate injection (DMI) at 0 and 24 hours and an IV injection with 0.9% sodium chloride solution at 48 and 72 hours. Blood samples were collected at 0, 6, 12, 24, 30, 36, 48, 72, 96, and 168 hours, and WBC parameters were evaluated using linear mixed-effects models.
Results:
Leukocyte count, neutrophil count, and neutrophil-to-lymphocyte ratio were increased at 6 hours after DMI. Mean leukocyte count peaked 6 hours after DMI and exceeded the reference interval; however, not all horses had peaks above the reference interval. Neutrophilia was observed in all horses, with peak values 6 hours after DMI. Lymphocyte, monocyte, and eosinophil counts were decreased at 6 hours after DMI, with complete suppression of eosinophils. Myeloperoxidase index was increased only at 6 hours after the second DMI. Neut-X was decreased at 12 hours after DMI, and Neut-Y did not change up to 156 hours after the first DMI. Most parameters returned to baseline at 48 to 72 hours.
Conclusions:
Repeated IV dexamethasone administration induces recognizable changes in leukograms in healthy horses with transient neutrophilia combined with increased leukocyte counts and neutrophil-to-lymphocyte ratios and decreased lymphocyte, monocyte, and eosinophil counts.
Clinical Relevance:
Recognition of glucocorticoid-induced changes is important for accurate interpretation of hematologic findings in horses receiving glucocorticoids.
611
项与 地塞米松磷酸钠 相关的新闻（医药）2026-08-10
– Publication details the discovery and
preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action
–
– Findings demonstrate differentiated menin binding and activity against certain resistance-associated mutations, further supporting ziftomenib’s potential across genetically defined acute leukemias –
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today announced the publication of a manuscript in
Blood
, the flagship journal of the American Society of Hematology, detailing the discovery and preclinical development of ziftomenib, a potent and selective menin inhibitor approved by the U.S. Food and Drug Administration in 2025 for adult patients with relapsed or refractory
NPM1
-mutated acute myeloid leukemia (AML).
The publication describes the scientific foundation underlying ziftomenib’s development, including its differentiated binding profile, potent and selective inhibition of the menin-KMT2A interaction, activity across multiple genetically defined leukemia models, and activity against certain treatment-emergent MEN1 mutations associated with resistance to other menin inhibitors.
ezstandalone.cmd.push(function () {
ezstandalone.showAds(131);
});
“The publication in
Blood
captures the remarkable scientific journey that led to ziftomenib, from identifying the menin-KMT2A interaction as a compelling therapeutic target to designing a potent and selective inhibitor with the properties needed for clinical development,” said Francis Burrows, Ph.D., Chief Scientific Officer of Kura Oncology. “The findings also provide important insight into the molecular properties that distinguish ziftomenib and supported its advancement from discovery through clinical development.”
Researchers from the University of Michigan pioneered the discovery of small molecules that target the interaction between menin and KMT2A, which plays an important role in leukemias with genetic changes such as
NPM1
mutations and
KMT2A
rearrangements. A collaboration between the University of Michigan and Kura Oncology, initiated in 2014, ultimately led to the development of ziftomenib, a menin inhibitor that Kura Oncology subsequently advanced through clinical development and FDA approval.
Study findings in preclinical leukemia models
As reported in
Blood
, across
KMT2A
-rearranged,
NPM1
-mutated and
NUP98
-rearranged leukemia models, ziftomenib demonstrated potent on-target activity, including suppression of key KMT2A-regulated genes such as
MEIS1
and
HOXA9
, induction of differentiation, and reduced leukemia cell viability.
Ziftomenib also was shown to induce leukemia regression and extended survival in multiple xenograft and patient-derived xenograft models, including durable responses observed after treatment discontinuation in a patient-derived model.
The research further evaluated ziftomenib against treatment-emergent
MEN1
mutations associated with resistance to menin inhibition. Researchers found that ziftomenib retained activity against certain resistance-associated menin mutations while other menin inhibitors did not, providing additional insight into ziftomenib’s differentiated binding pro the molecular determinants of resistance. Clinical studies have shown a low frequency of treatment-emergent MEN1 resistance mutation with ziftomenib; in KOMET-001, MEN1-M3271 emerged in only 1 of 29 evaluable patients.
i
“Ziftomenib represents the culmination of years of discovery, development, and dedication from an extraordinary team of scientists, clinicians, and colleagues who share a common goal: making a meaningful difference for patients,” said Troy E. Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “This publication provides important scientific validation of the properties that enabled ziftomenib to advance from an early discovery program to an approved medicine for adult patients with relapsed or refractory
NPM1
-mutated AML. More importantly, these findings reinforce our conviction in ziftomenib’s potential as a foundational therapy across the AML treatment continuum as we continue to pursue combination strategies with established standards of care and development across molecularly defined patient populations.”
Kura continues to advance ziftomenib as a potential foundational therapy across the AML treatment continuum by combining it with multiple standards of care in molecularly defined patient populations. These efforts are designed to build upon ziftomenib’s established activity in
NPM1
-mutated AML and expand its potential benefit to additional patients with menin-dependent acute leukemias, which represent up to 50% of eligible patients.
About Ziftomenib
Ziftomenib (marketed as KOMZIFTI
®
in the U.S.) is a once-daily, oral menin inhibitor approved by the U.S. Food and Drug Administration for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible
NPM1
mutation who have no satisfactory alternative treatment options. Ziftomenib is being studied across the AML treatment continuum, including in combination studies in newly diagnosed and relapsed or refractory
NPM1
-mutated AML,
KMT2A
-rearranged AML, and
FLT3
-mutated AML. Ziftomenib is also being explored in additional oncology indications, including advanced gastrointestinal stromal tumors.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the
Kura website
and follow us on
X
and
LinkedIn
.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the potential therapeutic pro clinical utility of ziftomenib; ziftomenib’s potential as a foundational therapy across the AML treatment continuum; the potential significance of preclinical findings; the potential to expand the benefit of ziftomenib to additional patient populations; and Kura’s ongoing and planned clinical development of ziftomenib, including combination strategies with established standards of care. Factors that may cause actual results to differ materially include the risk that preclinical findings may not be predictive of clinical results; risks related to the conduct, timing, enrollment, and results of clinical trials; regulatory developments; and other risks associated with the process of discovering, developing, and commercializing drugs that are safe and effective for use as human therapeutics, and the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
IMPORTANT SAFETY INFORMATION FOR KOMZIFTI FROM THE U.S. PRESCRIBING INFORMATION
Boxed WARNING: DIFFERENTIATION SYNDROME
Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI, and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement.
WARNINGS AND PRECAUTIONS
Differentiation Syndrome
KOMZIFTI can cause fatal or life-threatening differentiation syndrome (DS). DS is associated with rapid proliferation and differentiation of myeloid cells. Symptoms of DS, including those seen in patients treated with KOMZIFTI, may include fever, hypoxia, joint pain, hypotension, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, acute kidney injury, and rashes.
In the clinical trial, DS occurred in 29 (26%) of 112 patients with R/R AML with an
NPM1
mutation who were treated with KOMZIFTI at the recommended dosage. DS was Grade 3 in 13% and fatal in two patients. In broader evaluation of all patients with any genetic form of AML treated with KOMZIFTI monotherapy in clinical trials, DS occurred in 25% of patients. Four fatal cases of DS occurred out of 39 patients with
KMT2A
-rearranged AML treated with KOMZIFTI. KOMZIFTI is not approved for use in patients with
KMT2A
-rearranged AML.
In the 112 patients with an
NPM1
mutation, DS was observed with and without concomitant hyperleukocytosis, in as early as 3 days and up to 46 days after KOMZIFTI initiation. The median time to onset was 15 days. Two patients experienced more than one DS event. Treatment was interrupted and resumed in 15 (13%) patients, while it was permanently discontinued in 2 (2%) patients.
Prior to starting treatment with KOMZIFTI, reduce the WBC counts to less than 25 x 10⁹/L. If DS is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring. Resume treatment with KOMZIFTI at the same dose level when signs and symptoms improve and are Grade 2 or lower. Taper corticosteroids over a minimum of 3 days after adequate control or resolution of symptoms. Symptoms of DS may recur with premature discontinuation of corticosteroid treatment.
QTc Interval Prolongation
KOMZIFTI can cause QTc interval prolongation. In the clinical trial, QTc interval prolongation was reported as an adverse reaction in 12% of 112 patients treated with KOMZIFTI at the recommended dosage for R/R AML with an
NPM1
mutation. QTc interval prolongation was Grade 3 in 8% of patients. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 9% of patients, and the increase from baseline QTcF was greater than 60 msec in 12% of patients. KOMZIFTI dose reduction was required for 1% of patients due to QTc interval prolongation. QTc prolongation occurred in 14% of the 42 patients less than 65 years of age and in 10% of the 70 patients 65 years of age or older.
Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with KOMZIFTI. Perform an ECG prior to initiation of treatment with KOMZIFTI, and do not initiate KOMZIFTI in patients with QTcF > 480 msec. Perform an ECG at least once weekly for the first four weeks on treatment, and at least monthly thereafter. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms (Grade 3). In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of KOMZIFTI with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsades de Pointes, other serious arrhythmias, and sudden death.
Embryo-Fetal Toxicity
Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 3 months after the last dose.
ADVERSE REACTIONS
Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).
Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. Adverse reactions that required dose interruption in ≥ 2% of patients included infection without an identified pathogen (15%), differentiation syndrome (13%), febrile neutropenia (5%), pyrexia (4%), electrocardiogram QT prolonged (4%), leukocytosis (4%), bacterial infection (3%), cardiac failure (2%), cholecystitis (2%), diarrhea (2%), pruritus (2%), and thrombosis (2%). Dose reduction of KOMZIFTI due to an adverse reaction occurred in 4% of patients. Permanent discontinuation of KOMZIFTI due to an adverse reaction occurred in 21% of patients. Adverse reactions that required permanent discontinuation of KOMZIFTI in ≥ 2% of patients were infection without an identified pathogen (8%), bacterial infection (4%), cardiac arrest (2%), and differentiation syndrome (2%).
Most common (≥ 20%) adverse reactions, including laboratory abnormalities
, were aspartate aminotransferase increased (53%), infection without an identified pathogen (52%), potassium decreased (52%), albumin decreased (51%), alanine aminotransferase increased (50%), sodium decreased (49%), creatinine increased (45%), alkaline phosphatase increased (41%), hemorrhage (38%), diarrhea (36%), nausea (35%), fatigue (34%), edema (30%), bacterial infection (28%), musculoskeletal pain (28%), bilirubin increased (27%), potassium increased (26%), differentiation syndrome (26%), pruritus (23%), febrile neutropenia (22%), and transaminases increased (21%).
DRUG INTERACTIONS
Drug interactions may occur when KOMZIFTI is concomitantly used with:
Strong or Moderate CYP3A4 Inhibitors: Monitor patients more frequently for KOMZIFTI-associated adverse reactions.
Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of KOMZIFTI.
Gastric Acid Reducing Agents: Avoid concomitant use of KOMZIFTI with proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), or locally acting antacids. If concomitant use with H2RAs or locally acting antacids cannot be avoided, modify KOMZIFTI administration time.
Take KOMZIFTI 2 hours before or 10 hours after administration of an H2 receptor antagonist.
Take KOMZIFTI 2 hours before or 2 hours after administration of a locally acting antacid.
Drugs that Prolong the QTc Interval: Avoid concomitant use of KOMZIFTI. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms.
USE IN SPECIFIC POPULATIONS
Pregnancy:
Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to starting KOMZIFTI.
Lactation:
Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with KOMZIFTI and for 2 weeks after the last dose.
Infertility:
Based on findings in animals, KOMZIFTI may impair fertility in females and males of reproductive potential.
Please see full
Prescribing Information
, including
Boxed WARNING
.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
i
Erba H, Wang E, Issa G, et al.
Activity, Tolerability, and Resistance Pro the Menin Inhibitor
Ziftomenib
in Adults
With
Relapsed/Refractory NPM1-Mutated AML.
Clinical Lymphoma, Myeloma & Leukemia.
2023;23(Suppl 1):S304-S305. doi:
10.1016/S2152-2650(23)01067-4
.
上市批准临床结果ASH会议临床研究
2026-08-09
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
Clinical Infectious Diseases Volume 82 Issue Supplement_4
临床传染病学 82卷 增刊4期
https://academic.oup.com/cid/issue/82/Supplement_4
SUPPLEMENT（增刊）
IDWeek Industry Highlights 2025
传染病之周2025 行业亮点
SUPPLEMENT ARTICLES（增补论著）
1
Selected Industry Highlights From IDWeek 2025
传染病之周2025 精选行业亮点
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S85–S86, https://doi.org/10.1093/cid/ciag206
2
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
HIV感染者内脏腹部脂肪过多的不同表现：两例临床病例展示特沙莫瑞林与胰高血糖素样肽-1受体激动剂的不同治疗路径
Robin Beach and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S87–S91, https://doi.org/10.1093/cid/ciag121
3
Metagenomic Next-generation Sequencing in Central Nervous System Infections: Clinical Strategies, Evidence, and Best Practices
宏基因组二代测序在中枢神经系统感染中的应用：临床策略、证据与最佳实践
Greer Waldrop and Sumanth P Reddy
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S92–S99, https://doi.org/10.1093/cid/ciag120
Clinical Infectious Diseases Volume 82 Issue 5
临床传染病学 82卷 5期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Vaccination Detail, Detroit Industry
疫苗接种细节，底特律工业
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page i, https://doi.org/10.1093/cid/ciag119
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag180
Voices of ID（传染病之声）
3
Infected With the Academic Bug
染上学术热
Sigrun Einarsdottir
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 743–744, https://doi.org/10.1093/cid/ciaf546
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
4
Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care
C反应蛋白对乌干达接受世界卫生组织推荐治疗方案的晚期HIV疾病患者住院和死亡的预测价值
Elizabeth L Schwartz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 745–752, https://doi.org/10.1093/cid/ciaf560
5
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
塞马谷肽对HIV感染者认知功能的影响：一项随机对照试验
Ornina Atieh and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 753–761, https://doi.org/10.1093/cid/ciaf577
6
Earlier Initiation of Treatment Following HIV Acquisition Reduces Non-AIDS-defining Malignancy Risk
HIV感染后尽早启动治疗可降低非艾滋病相关性恶性肿瘤风险
Iris A J van der Wulp and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 762–772, https://doi.org/10.1093/cid/ciaf595
7
Let's Get It Started: Early Antiretroviral Treatment After HIV Acquisition Reduces Non–AIDS-Defining Malignancies
让我们开始吧：HIV感染后尽早启动抗逆转录病毒治疗可减少非艾滋病相关性恶性肿瘤
Nancy Crum
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 773–775, https://doi.org/10.1093/cid/ciaf596
8
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006–2023
2006–2023年西班牙HIV感染者年龄相关健康结局的趋势
Javier Martínez-Sanz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 776–784, https://doi.org/10.1093/cid/ciaf622
9
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
当代抗逆转录病毒方案随机试验中新发HIV-1耐药性
Josep M Llibre and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 785–798, https://doi.org/10.1093/cid/ciaf471
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
10
Mycobacterium tuberculosis Transmission in Healthcare Settings: A Systematic Review of Frequency, Risk Factors, and Exposure Conditions
医疗机构中结核分枝杆菌传播：频率、危险因素及暴露条件的系统综述
Fizza Manzoor and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 799–807, https://doi.org/10.1093/cid/ciag053
Medical Microbiology（医学微生物学）
11
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
脑脊液宏基因组二代测序：一家三级转诊医院首年经验
Sergio Alvarez Mulett and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 808–814, https://doi.org/10.1093/cid/ciaf390
12
Navigating Nomenclature in Patient Care: Taxonomy Considerations From the College of American Pathologists’Microbiology Committee
患者诊疗中的命名导航：美国病理学家学会微生物学委员会的分类学考量
Jennifer Dien Bard and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 815–821, https://doi.org/10.1093/cid/ciaf474
13
Implementing Point-of-Care Testing in Infectious Diseases
在感染性疾病中实施床旁检测
Jean-Claude Nguyen Van and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 822–828, https://doi.org/10.1093/cid/ciaf650
Mycobacterial Infections（分枝杆菌感染）
14
Impact of Diabetes Mellitus in Tuberculosis (TB) Patients on TB Transmission
糖尿病对结核病（TB）患者TB传播的影响
Chuan-Chin Huang and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 829–840, https://doi.org/10.1093/cid/ciaf647
15
Association of Mycobacterium avium paratuberculosis With Crohn's Disease: A Large Multicenter Study From a Tuberculosis-Endemic Region
副结核分枝杆菌与克罗恩病的关联：来自结核病流行地区的一项大型多中心研究
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 841–847, https://doi.org/10.1093/cid/ciaf738
16
Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois
高移民背景下的短程结核病预防性治疗：库克县（伊利诺伊州）1HP方案的早期经验
Samuel Starke and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 848–851, https://doi.org/10.1093/cid/ciaf723
17
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
低剂量英夫利昔单抗在中枢神经系统结核炎性并发症中的作用：一项回顾性队列研究
Selwyn Selva Kumar D and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 852–856, https://doi.org/10.1093/cid/ciaf573
18
Targeting Inflammation in Tuberculous Meningitis Treatment
靶向结核性脑膜炎治疗中的炎症
Guy E Thwaites
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 857–859, https://doi.org/10.1093/cid/ciaf574
Pediatric and Maternal Infectious（儿科与孕产妇感染）
19
A 15-year Single-center Analysis of Late-onset Group B Streptococcus Infection Correlating Clinical Severity With Pathogen Virulence Determinants
晚发型B族链球菌感染的15年单中心分析：临床严重程度与病原体毒力因子的相关性
Carl Britto and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 860–867, https://doi.org/10.1093/cid/ciaf603
20
Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households — A Randomized Clinical Trial
评估皮肤和软组织感染儿童及其家庭的个人与环境去定植策略——一项随机临床试验
Alaina L Robinson and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 868–877, https://doi.org/10.1093/cid/ciaf627
Surgical Infectious Diseases（外科感染）
21
Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE
万古霉素耐药肠球菌（VRE）主动围手术期预防对VRE定植肝移植受者的影响
Giulia Jole Burastero and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 878–887, https://doi.org/10.1093/cid/ciaf121
22
Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis
头孢菌素与非头孢菌素类抗生素在初次关节置换术围手术期预防中的比较：系统综述与荟萃分析
Rita Igwilo-Alaneme and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 888–900, https://doi.org/10.1093/cid/ciag172
Photo Quizzes（影像问答）
23
Safari Souvenir: A Case of Fever in a Returning Traveler
safari纪念品：一例返程旅行者发热病例
Nicole L Kusnik and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 901–903, https://doi.org/10.1093/cid/ciag129
24
Diagnostic Pitfalls—When First Appearances Can Deceive
诊断陷阱——当表象具有欺骗性
Annie Caldwell and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 904–907, https://doi.org/10.1093/cid/ciag044
Clinical Trials（临床试验）
25
Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy
远程治疗监测设备与综合护理平台在门诊肠外抗微生物治疗中的评估
Emily A Siegrist and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e899–e909, https://doi.org/10.1093/cid/ciag009
26
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
多替拉韦降低人T淋巴细胞病毒1型前病毒载量并改善神经系统预后：一项2期对照试验
Carlos Brites and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e910–e920, https://doi.org/10.1093/cid/ciag163
27
Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy
多替拉韦似乎可降低人T淋巴细胞病毒1型（HTLV-1）前病毒载量：HTLV-1相关脊髓病治疗的新兴理性方法
Eric A Meyerowitz
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e921–e922, https://doi.org/10.1093/cid/ciag164
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers
长效新冠与急性新冠疫苗接种后综合征的临床表现重叠：表型、严重程度及生物标志物
Lawrence Purpura and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e923–e931, https://doi.org/10.1093/cid/ciaf624
29
Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness
将基因组数据整合入检测阴性设计以估计谱系特异性COVID-19疫苗有效性
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e932–e941, https://doi.org/10.1093/cid/ciag059
Hepatitis（肝炎）
30
Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV
HIV感染者经直接抗病毒药物治疗丙型肝炎病毒后肝细胞癌的风险
Daniela K van Santen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e942–e950, https://doi.org/10.1093/cid/ciaf635
31
Fatal Overdose, Acute Viral Hepatitis, and HIV Attributed to Injection Drug Use, Appalachian Region of the United States, 2000–2023
阿巴拉契亚地区2000–2023年注射吸毒导致的致命过量、急性病毒性肝炎及HIV
Danae Bixler and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e951–e959, https://doi.org/10.1093/cid/ciaf730
32
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
利用大型商业实验室剩余血清估算丙型肝炎患病率及病毒清除率：2023年11月至2024年9月
Megan G Hofmeister and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e960–e966, https://doi.org/10.1093/cid/ciag007
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
33
State AIDS Drug Assistance Programs’Contribution to the US Viral Suppression, 2015–2022
美国各州艾滋病药物援助项目对全美病毒抑制的贡献，2015–2022年
Kathleen A McManus and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e967–e973, https://doi.org/10.1093/cid/ciag034
34
Centering AIDS Drug Assistance Programs in the US HIV Response
将艾滋病药物援助项目置于美国HIV应对的核心
Benjamin P Linas
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e974–e975, https://doi.org/10.1093/cid/ciag035
35
Association of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
南非HIV感染女性中免疫缺陷和HIV病毒血症与宫颈癌前病变及癌症风险的关联
Yann Ruffieux and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e976–e983, https://doi.org/10.1093/cid/ciag093
36
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies
MK-8527（一种口服核苷逆转录酶转位抑制剂）在既往未接受过抗逆转录病毒治疗的HIV-1感染成人中的抗逆转录病毒活性、药代动力学及安全性：来自两项开放标签1期研究的结果
Russ P Carstens and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e984–e991, https://doi.org/10.1093/cid/ciag135
37
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
床旁尿液替诺福韦药物浓度反馈咨询改善美国男男性行为者长期暴露前预防用药依从性——一项先导随机对照试验
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e992–e995, https://doi.org/10.1093/cid/ciag080
Mycobacterial Infections（分枝杆菌感染）
38
Diagnostic Accuracy of the STANDARD F TB-Feron FIA Assay for Tuberculosis Infection in Vietnam: A Cross-Sectional Study
STANDARD F TB-Feron FIA检测在越南结核感染诊断中的准确性：一项横断面研究
Han Thi Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e996–e1004, https://doi.org/10.1093/cid/ciaf561
39
Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis
有结核分枝杆菌家庭接触史儿童中的无症状结核病
Humphrey Mulenga and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1005–e1013, https://doi.org/10.1093/cid/ciaf562
40
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment
利福平暴露及临床基线协变量对肺结核治疗反应影响的深入认识
Marie Wijk and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1014–e1022, https://doi.org/10.1093/cid/ciaf586
41
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures
靶向免疫治疗的结核感染筛查建议：美国处方信息、临床资源与质量指标的比较
Matthew T Murrill and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1023–e1035, https://doi.org/10.1093/cid/ciaf628
42
Pharmacokinetics of Dexamethasone in Tuberculous Meningitis
地塞米松在结核性脑膜炎中的药代动力学
Jose M Calderin and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1036–e1042, https://doi.org/10.1093/cid/ciaf642
43
One Piece in the Puzzle of Tuberculous Meningitis: Dexamethasone Pharmacokinetics
结核性脑膜炎拼图中的一块：地塞米松药代动力学
Tjip S van der Werf and Marieke G G Sturkenboom
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1043–e1044, https://doi.org/10.1093/cid/ciaf644
44
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
临床表型用于结核精准医学的未来前景——一种临床管理方法
Katarina Niward and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1045–e1052, https://doi.org/10.1093/cid/ciaf663
Pediatric and Maternal Infectious Diseases（儿科与孕产妇感染）
45
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa
南非夸祖鲁-纳塔尔省接受新型及重新利用药物治疗耐多药/利福平耐药结核病的女性的母婴预后
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1053–e1062, https://doi.org/10.1093/cid/ciaf593
46
Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa
南非耐多药/利福平耐药结核病孕妇与全口服6个月方案：一例系列患者的经验
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1063–e1071, https://doi.org/10.1093/cid/ciag032
47
Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors
HCMV血清阳性女性孕期及产后人巨细胞病毒（HCMV）排毒和T细胞免疫应答：患病率、自然史及危险因素
Shari Sapuan and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1072–e1082, https://doi.org/10.1093/cid/ciag076
Vaccines（疫苗）
48
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
奥密克戎BA.1适配BNT162b2 COVID-19疫苗第四剂在18–55岁成人中的安全性和免疫原性
Patricia Winokur and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1083–e1092, https://doi.org/10.1093/cid/ciag026
49
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
AS01E佐剂呼吸道合胞病毒（RSV）预融合F蛋白疫苗在18–49岁RSV高风险成人中与≥60岁成人的免疫原性和安全性比较
Essack Mitha and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1093–e1103, https://doi.org/10.1093/cid/ciag058
50
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis
RSVpreF和RSVpreF3疫苗在预防老年人RSV相关住院和急诊就诊中的真实世界有效性：一项荟萃分析
Dewan Md Sumsuzzman and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1104–e1111, https://doi.org/10.1093/cid/ciag107
51
Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
实体器官移植受者的呼吸道合胞病毒疫苗接种：mRNA-1345三期试验中期结果
Erick F Mayer and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1112–e1121, https://doi.org/10.1093/cid/ciag108
Photo Quiz（影像问答）
52
Crusted, Chronic, and Confusing
结痂、慢性化与困惑
Luisa Hurtado-Rossi and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1122–e1125, https://doi.org/10.1093/cid/ciaf583
Correspondence（读者来信）
53
Unmasking the Hidden Guests: Referral and Secondary Infection Biases in Cutibacterium Endocarditis
揭开隐藏的访客：Cutibacterium心内膜炎中的转诊偏倚和二次感染偏倚
Shuo Li and Lin Wang
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1126, https://doi.org/10.1093/cid/ciaf733
54
Reply to Willoughby on the Demise of the Milwaukee Protocol for Rabies
对Willoughby关于密尔沃基狂犬病方案终结的回复
Alan C Jackson and Thiravat Hemachudha
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1126–e1127, https://doi.org/10.1093/cid/ciaf734
55
Estimating Vaccine Effectiveness Against Symptomatic Infection From Its Effectiveness Against Asymptomatic Infection
从无症状感染的疫苗有效性估算有症状感染的疫苗有效性
Eyal Shahar
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1127–e1128, https://doi.org/10.1093/cid/ciaf735
56
Contextualizing On-Therapy Resistance Development With Novel Antibiotics: Interplay Between Timing of Therapy Initiation and Critical Illness–Linked Pharmacokinetic/Pharmacodynamic Unpredictability
新型抗生素治疗中耐药产生的情境化解读：治疗启动时机与危重疾病相关药代动力学/药效学不可预测性之间的相互作用
Dilip Dubey and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1128–e1129, https://doi.org/10.1093/cid/ciag010
57
The Clinical Thermometer as the First Home Test for Infectious Disease
临床体温计：感染性疾病的首个家用检测工具
Michele Augusto Riva
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1129–e1130, https://doi.org/10.1093/cid/ciag030
58
Methodology Misrepresented: Correcting the Record on the American Thoracic Society Community-acquired Pneumonia Guideline Process
方法论被歪曲：更正美国胸科学会社区获得性肺炎指南制定过程的记录
Kevin C Wilson and Eyal Oren
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1130–e1131, https://doi.org/10.1093/cid/ciag040
59
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
关于早期卡介苗接种对新生儿和婴儿死亡率影响的误导性评论
Peter Aaby and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1131–e1132, https://doi.org/10.1093/cid/ciag065
60
Questioning Non-inferiority: Methodological Concerns in the Meta-analysis of Oral vs Intravenous Therapy for Staphylococcus aureus Bacteremia
质疑非劣效性：金黄色葡萄球菌菌血症口服与静脉治疗荟萃分析中的方法学问题
Dawd S Siraj and Fauzia Hollnagel
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1132–e1133, https://doi.org/10.1093/cid/ciag070
61
Problems With Electronic Health Record Penicillin Allergy Mislabeling and Recommendations for Their Correction
电子健康记录中青霉素过敏标注错误的问题及纠正建议
David J Witt and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1134, https://doi.org/10.1093/cid/ciag086
62
Complex Problem, Digital Cure? Rethinking Penicillin Allergy Relabeling Using Technology-Enabled Care
复杂问题，数字解药？利用技术赋能护理重新思考青霉素过敏重新标注
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1135–e1137, https://doi.org/10.1093/cid/ciag084
Clinical Infectious Diseases Volume 82 Issue Supplement_5
临床传染病学 82卷 增刊5期
https://academic.oup.com/cid/issue/
SUPPLEMENT（增刊）
ADVANCE-ID: Conducting Innovative Clinical Trials and Promoting Access for Antibiotics in Asia
ADVANCE-ID：在亚洲开展创新临床试验并推动抗生素可及性
SUPPLEMENT ARTICLES（增补论著）
1
Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the “Antimicrobial Resistance Hot Zone”
推进感染病临床证据：面向亚洲——这一"耐药热点区域"——的感染性疾病临床试验网络
David L Paterson
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S101–S104, https://doi.org/10.1093/cid/ciag122
2
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World
多重耐药革兰阴性杆菌管理的全球调查：高收入国家与世界其他地区的实践差异
Abi Manesh and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S105–S115, https://doi.org/10.1093/cid/ciag025
3
Efficacy and Safety of Newer Antibiotics Versus Generic Antibiotics for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
新型抗生素与仿制抗生素治疗医院获得性及呼吸机相关性细菌性肺炎的疗效与安全性：随机对照试验的系统综述与荟萃分析
Anh T K Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S116–S125, https://doi.org/10.1093/cid/ciag045
4
Antibiotic Clinical Trials: A Review of the Past, Present Challenges, and Potential Solutions
抗生素临床试验：回顾过去、当前挑战及潜在解决方案
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S126–S137, https://doi.org/10.1093/cid/ciag017
5
Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design
采用优效性设计开展新型抗菌药物临床试验的考量
David L Paterson and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S138–S146, https://doi.org/10.1093/cid/ciag207
6
Consent Modes and Consent Rates in Randomized Controlled Trials for Severe Infections: A Scoping Review
严重感染随机对照试验中的知情同意方式与同意率：范围性综述
Yiyun Shou and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S147–S153, https://doi.org/10.1093/cid/ciaf715
7
Challenges to Accessing Newer Antibiotics for Multidrug-resistant Bacterial Infections in Asia: A Literature Review of Multi-Stakeholder Perspectives
亚洲多重耐药细菌感染中获取新型抗生素的挑战：多利益相关方视角的文献综述
Alec F Aligui and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S154–S161, https://doi.org/10.1093/cid/ciag024
Clinical Infectious Diseases Volume 82 Issue 6
临床传染病学 82卷 6期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（传染病艺术长河）
1
Cover Illustration for Camus' The Plague, 1948
加缪《鼠疫》封面插画，1948年
Michael B Grizzard and Mary Grizzard
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page i, https://doi.org/10.1093/cid/ciag182
In the Literature（文献札记）
2
In the Literature
文献札记
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag181
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Contemporary Ambulatory Approach to Adult Fever of Unknown Origin
前沿综述：成人不明原因发热的当代门诊诊疗方案
William F Wright and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 909–926, https://doi.org/10.1093/cid/ciag158
Ethics Rounds（伦理巡诊）
4
Antibiotics in Hospice: Applying the Four-Quadrant Approach to Improve Patient-Centered Care
安宁疗护中的抗菌药物使用：运用四象限诊疗模式优化以患者为中心的照护
Patrick D Crowley and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 927–930, https://doi.org/10.1093/cid/ciag057
Voices of ID（传染病之声）
5
I Died—and Was Brought Back to Life—Twice
我两次濒死，又重获新生
Richard E. Sutton
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 931–933, https://doi.org/10.1093/cid/ciaf612
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
6
Using Encounter-Level Data for Risk-Adjustment of Antimicrobial Use Comparisons: Feasibility and Variable Selection
利用就诊层面数据开展抗菌药物使用对比的风险校正：可行性与变量筛选研究
Rebekah W Moehring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 934–943, https://doi.org/10.1093/cid/ciaf682
7
Moving Closer to Patient-Level Risk Adjustment for Hospital Antimicrobial Use
推进住院患者抗菌药物使用的个体化风险校正体系构建
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 944–945, https://doi.org/10.1093/cid/ciaf683
8
Macrolide and Nonmacrolide Resistance After 36 Months of Mass Azithromycin Distribution in Burkina Faso: A Cluster Randomized Trial
布基纳法索大规模阿奇霉素分发36个月后大环内酯类与非大环内酯类耐药情况：一项整群随机对照试验
Catherine E Oldenburg and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 946–953, https://doi.org/10.1093/cid/ciag051
9
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients: A Pragmatic, Randomized Trial
基于社区获得性肺炎发病概率为住院患者个体化选用抗菌药物：一项实用性随机对照试验
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 954–961, https://doi.org/10.1093/cid/ciag126
10
ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse
抗菌药物管理中的ALARA原则：借鉴辐射安全理念管控抗生素过度使用
Zachary T Aldewereld and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 962–967, https://doi.org/10.1093/cid/ciaf688
Clinical Practice and Policy（临床实践与医疗政策）
11
Assessment of an Infectious Disease eConsult Service at a Large Mid-Atlantic Healthcare System
美国中大西洋大型医疗体系感染病线上会诊服务应用效果评估
Ava Hunt and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 968–970, https://doi.org/10.1093/cid/ciaf736
12
H.U.S.T.L.E: A Consult Fitness Guide for Infectious Diseases Providers
H.U.S.T.L.E指南：感染科医师会诊工作实操指南
Gonzalo Bearman and Priya Nori
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 971–975, https://doi.org/10.1093/cid/ciaf672
13
More Than a Message: Death by a 1000 “Chats”
不止简单文字沟通：无休止线上问诊带来的诊疗困境
Darcy Wooten and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 976–978, https://doi.org/10.1093/cid/ciag094
14
The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025
公共卫生支柱职能削弱：美国免疫实践咨询委员会的职能变迁与2025年6月后疫苗政策走向
Edwin J Asturias and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 979–985, https://doi.org/10.1093/cid/ciag042
15
Worldwide Impact of ACIP's 2025 Overhaul
2025年美国免疫实践咨询委员会政策修订的全球影响
Louis Bont and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 986–987, https://doi.org/10.1093/cid/ciag043
Hepatitis（肝炎）
16
Trends in Reflexive Hepatitis C Virus Testing in a National US Laboratory: A Retrospective Study From 2018 to 2024
美国国家级实验室丙型肝炎病毒 reflex联动检测趋势：2018–2024年回顾性研究
Min Kyung Lee and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 988–992, https://doi.org/10.1093/cid/ciag227
17
Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women With Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: A Pharmacokinetic Study
合并阿片类物质使用障碍的产后丙肝治疗女性母乳中索磷布韦/维帕他韦药物浓度：药代动力学研究
Catherine A Chappell and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 993–996, https://doi.org/10.1093/cid/ciaf443
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
18
Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study
当前抗逆转录病毒治疗时代，基于CD4计数与年龄划分的HIV感染者社区获得性肺炎、带状疱疹发病风险：一项纵向队列研究
Elsemieke te Linde and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 997–1006, https://doi.org/10.1093/cid/ciaf686
19
Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance
病毒学抑制HIV感染者转换为比克替拉韦/丙酚替诺福韦/恩曲他滨方案或多替拉韦+富马酸替诺福韦二吡呋酯/恩曲他滨方案：有无替诺福韦耐药人群真实世界转归
Alain Makinson and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1007–1014, https://doi.org/10.1093/cid/ciaf726
20
Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
HIV感染者转换长效卡博特韦/利匹韦林后的乙肝转归：病毒再激活、新发感染及不同血清学状态下肝脏安全性
Alberto Foncillas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1015–1022, https://doi.org/10.1093/cid/ciag023
21
Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications
长效注射卡博特韦联合利匹韦林治疗发生病毒学失败：亚型、血药浓度、耐药突变及临床诊疗意义分析
Maria Mazzitelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1023–1031, https://doi.org/10.1093/cid/ciag046
22
What Are the Causes and Consequences of Virological Failure on Long-acting Cabotegravir/Rilpivirine?
长效卡博特韦/利匹韦林方案病毒学失败的诱因与临床后果
Andrew Hill and Chloe Orkin
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1032–1034, https://doi.org/10.1093/cid/ciag047
Parasitic Infections（寄生虫感染）
23
Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment
脑型疟疾与重症疟疾性贫血（其余重症疟疾亚型除外）与远期认知损伤相关
Paul Bangirana and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1035–1041, https://doi.org/10.1093/cid/ciaf712
24
Not All Forms of Severe Malaria Impair Long-term Cognition—More Characterization, More Questions
并非所有重症疟疾均会造成长期认知损害——仍需更多分层研究与探索
Karl B Seydel and Stephen T J Ray
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1042–1043, https://doi.org/10.1093/cid/ciaf713
25
Frequent Plasmodium ovale Recurrence in Coastal Tanzania
坦桑尼亚沿海地区卵形疟原虫高复发率研究
Kelly Carey-Ewend and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1044–1051, https://doi.org/10.1093/cid/ciag199
26
Invisible Malarias
隐匿性疟疾
J Kevin Baird
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1052–1053, https://doi.org/10.1093/cid/ciag201
Sexually Transmitted Infections（性传播疾病）
27
A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study
男男性行为人群及跨性别女性每日口服HIV联合性病暴露前预防（富马酸替诺福韦二吡呋酯/恩曲他滨加多西环素）先导随机对照试验：DuDHS研究
Troy Grennan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1054–1062, https://doi.org/10.1093/cid/ciaf043
28
A New Choice for Doxycycline Prophylaxis
多西环素暴露前预防新选择
Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1063–1064, https://doi.org/10.1093/cid/ciaf044
29
Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial
服用多西环素暴露后预防男性的耐药淋病奈瑟菌感染情况：ANRS 174 DOXYVAC子研究
Béatrice Berçot and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1065–1074, https://doi.org/10.1093/cid/ciaf591
30
Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic Over 96 Weeks: An Interrupted Time Series Analysis
大型性病诊疗中心多西环素暴露后预防96周持续有效率：间断时间序列分析
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1075–1078, https://doi.org/10.1093/cid/ciaf234
Photo Quiz（影像问答）
31
A 3-Year-Old Girl With a Chest Wall Mass
3岁女童胸壁肿块一例
Deema Gashgarey and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1079–1081, https://doi.org/10.1093/cid/ciag028
32
Why Are Gonorrhea Case Rates Declining in the United States? A Research Agenda
美国淋病报告病例数下降原因：后续研究方向展望
Kirstin I Oliveira Roster and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1082–1090, https://doi.org/10.1093/cid/ciaf690
33
Fever in a Man with Uncontrolled HIV
HIV控制不佳男性发热病例
Tristan Jones and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1091–1095, https://doi.org/10.1093/cid/ciag056
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
34
Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility—Massachusetts, USA, 2023
2023年美国马萨诸塞州：动物诊疗机构内动物与环境传播引发人感染产碳青霉烯酶大肠埃希菌病例
Ian M DeStefano and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1138–e1144, https://doi.org/10.1093/cid/ciaf541
35
Carbapenemase-Producing Enterobacterales in Pets: A New Threat From Veterinary Clinics
宠物携带产碳青霉烯酶肠杆菌目细菌：动物诊所带来的新型感染威胁
Vincent Perreten and Andrea Endimiani
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1145–e1147, https://doi.org/10.1093/cid/ciaf544
36
Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服药物激发试验：国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1148–e1162, https://doi.org/10.1093/cid/ciag082
37
Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服激发试验院内落地实施效果评估——基于国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1163–e1170, https://doi.org/10.1093/cid/ciag083
Bacterial Infections（细菌感染）
38
Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience
原发性椎体骨髓炎临床表现、26年长期发病趋势及治疗失败危险因素：梅奥诊所单中心经验
Takahiro Matsuo and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1171–e1180, https://doi.org/10.1093/cid/ciag048
39
The Management of Native Vertebral Osteomyelitis Remains Unchanged: Are Additional Trials Necessary?
原发性椎体骨髓炎诊疗方案无实质性更新：是否仍需开展更多临床试验？
Werner Zimmerli
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1181–e1183, https://doi.org/10.1093/cid/ciag049
40
Clinical Characteristics and Survival of Hospitalized Anthrax Patients with Pleural, Pericardial, or Peritoneal Fluid Collections
合并胸腔、心包、腹腔积液的住院炭疽患者临床特征与生存预后
Jon-Erik C Holty and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1184–e1193, https://doi.org/10.1093/cid/ciag113
41
Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care
单纯性尿路感染：从隐匿疾病负担到复杂诊疗体系的诊疗变革
Rafael Cantón and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1194–e1199, https://doi.org/10.1093/cid/ciaf705
Emerging Infections（新型感染）
42
Six Cases of Borealpox and Evidence of a Zoonotic Source: Alaska, 2020–2023
2020–2023年阿拉斯加6例北极痘病例及动物源性传播证据
Eric Q Mooring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1200–e1207, https://doi.org/10.1093/cid/ciaf497
43
Measles Without Rash During Acute Febrile Illness Surveillance in Tanzania, 2023–2024
2023–2024年坦桑尼亚急性发热监测中无皮疹麻疹病例
Saning'o Lukumay and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1208–e1215, https://doi.org/10.1093/cid/ciaf582
44
Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States
泰国归国旅行者罹患类鼻疽合并原生瓣膜心内膜炎
Akash Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1216–e1221, https://doi.org/10.1093/cid/ciag003
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
45
Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001–2019
2001–2019年美国HIV阳性与阴性人群肝细胞癌生存预后对比
Jennifer K McGee-Avila and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1222–e1231, https://doi.org/10.1093/cid/ciag137
46
Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
多替拉韦方案对比依非韦伦方案抗逆转录病毒治疗重大心血管不良事件风险：基于南非匿名常规医疗数据的模拟目标试验
Jienchi Dorward and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1232–e1241, https://doi.org/10.1093/cid/ciag155
47
Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-based Longitudinal Study
全面切换多替拉韦治疗期间HIV-1病毒载量抑制水平与耐药突变特征：一项人群纵向研究
Michael A Martin and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1242–e1251, https://doi.org/10.1093/cid/ciag161
48
Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
合并2型糖尿病的HIV感染者与非感染者肾脏及心血管并发症：瑞典HIV发病队列研究（COSMOHS）2010–2024数据
Isabela Killander Möller and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1252–e1261, https://doi.org/10.1093/cid/ciag261
49
Progression Risk in Cancer Patients with HIV Compared with Cancer Patients Without HIV
HIV阳性肿瘤患者相较于阴性患者的疾病进展风险
Derek Schneider and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1262–e1265, https://doi.org/10.1093/cid/ciag170
Infections in Older Adults（老年人群感染）
50
Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries
急性呼吸道感染老年患者呼吸道合胞病毒疾病负担：欧洲六国前瞻性研究
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1266–e1276, https://doi.org/10.1093/cid/ciag146
51
Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons
连续三个流行季欧洲老年呼吸道合胞病毒感染者健康相关生活质量调查
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1277–e1288, https://doi.org/10.1093/cid/ciag147
52
The Renaissance of Respiratory Syncytial Virus Diagnosis: How Understanding Burden Can Inform Clinical Practice and Demonstrate the Benefit of Vaccines
呼吸道合胞病毒诊断技术革新：明晰疾病负担指导临床实践、印证疫苗获益价值
Angela R Branche
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1289–e1291, https://doi.org/10.1093/cid/ciag148
Mycobacterial Infections（分枝杆菌感染）
53
Hidden in Success: Gendered Patterns of Suboptimal Care Engagement Among Tuberculosis Patients Who“Successfully” Completed Treatment in South Africa
治愈背后的隐忧：南非“治疗成功”结核患者就医依从性的性别差异
Andrew Medina-Marino and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1292–e1301, https://doi.org/10.1093/cid/ciaf714
54
Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings
两大高结核负担临床中心痰Xpert Ultra微量阳性成人及青少年结核患病率与预测因素
Caitlin Visek and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1302–e1310, https://doi.org/10.1093/cid/ciag019
55
“Trace-MTB” on Sputum Xpert Ultra: New Evidence for Interpretation in High-burden Settings
痰Xpert Ultra“微量结核分枝杆菌”阳性：高结核负担地区判读新证据
Bianca Sossen and Neil Martinson
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1311–e1312, https://doi.org/10.1093/cid/ciag018
56
Diagnostic Accuracy of Molecular Testing on Saliva and Oral Swabs for Pulmonary Tuberculosis
唾液与口腔拭子分子检测对肺结核的诊断效能
Deninson Alejandro Vargas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1313–e1321, https://doi.org/10.1093/cid/ciag055
57
Documenting Environmentally Acquired Mycobacterium intracellulare subsp. chimaera Pulmonary Disease Soon After Bronchiectasis Onset
支气管扩张发病后短期内确诊环境源性奇美拉胞内分枝杆菌肺病病例报道
Jennifer R Honda and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1322–e1325, https://doi.org/10.1093/cid/ciag015
58
We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness
我国对贝达喹啉耐药危机应对准备不足：呼吁完善临床与公共卫生防控体系
Gail Brenda Cross and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1326–e1332, https://doi.org/10.1093/cid/ciag008
Respiratory Infections（呼吸道感染）
59
Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus
呼吸道合胞病毒急性呼吸道感染住院患者远期临床结局
David Singer and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1333–e1344, https://doi.org/10.1093/cid/ciaf710
60
Microbial Detection in Community-Acquired Pleural Space Infections Using the BIOFIRE Joint Infection Panel and Individual Polymerase Chain Reaction Assays
采用BIOFIRE关节感染试剂盒与单重PCR检测社区获得性胸腔感染病原体
Portia Mira and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1345–e1352, https://doi.org/10.1093/cid/ciag050
61
Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis
新型商业化γ干扰素释放试验诊断结核分枝杆菌感染的效能：更新系统综述与荟萃分析
Lika Apriani and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1353–e1364, https://doi.org/10.1093/cid/ciag102
Viral Infections（病毒感染）
62
Symptomatic and Asymptomatic Norovirus Infections in Early Life; the PREVAIL Cohort, 2017–2020
婴幼儿诺如病毒显性与隐性感染：PREVAIL队列2017–2020年数据
Julia M Baker and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1365–e1374, https://doi.org/10.1093/cid/ciag033
63
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions—A Retrospective Cohort Study in the United States
≥18岁合并基础疾病成人带状疱疹分年龄发病风险：美国回顾性队列研究
Rachel A Cohen and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1375–e1383, https://doi.org/10.1093/cid/ciag095
64
Herpes Simplex Virus Type 1 Encephalitis: A Prospective Population-Based Cohort Study
1型单纯疱疹病毒性脑炎：一项基于人群的前瞻性队列研究
Lærke Storgaard Duerlund and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1384–e1392, https://doi.org/10.1093/cid/ciag136
Photo Quiz（影像问答）
65
Multifocal Cutaneous Abscesses
多发皮肤脓肿病例
Shrruthi Velavan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1393–e1396, https://doi.org/10.1093/cid/ciag074
Correspondence（读者来信）
66
New French Guidelines on Subcutaneous Antibiotic Therapy: A Response to Di Bella et al.
法国皮下注射抗生素新版指南发布——回应Di Bella等人研究
Emmanuel Forestier and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1397–e1398, https://doi.org/10.1093/cid/ciag088
67
Time to Appropriate Therapy and Antimicrobial Resistance-Attributable Mortality
抗菌药物及时给药时长与耐药相关死亡风险
Tatsuhiko Nanri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1398, https://doi.org/10.1093/cid/ciag087
68
Is Time to Appropriate Therapy a Mediator of Mortality Associated With Antimicrobial Resistance?
抗菌药物及时给药时长是否介导耐药相关死亡风险？
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1398–e1399, https://doi.org/10.1093/cid/ciag090
69
Request for Additional Details on the COPAT Trial
恳请补充COPAT试验详细研究数据
Brad Spellberg and Bassam Ghanem
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1399, https://doi.org/10.1093/cid/ciag100
70
Additional Details on the COPAT Trial
COPAT试验补充研究细节回复
Joy J Juskowich and Arif R Sarwari
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1399–e1401, https://doi.org/10.1093/cid/ciag103
71
Zinc: An Oft-forgotten Component in the Management of Diarrhea
锌剂：腹泻治疗中常被忽视的关键药物
Indi Trehan
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1401, https://doi.org/10.1093/cid/ciag111
72
I Zinc, Therefore I Am: Context is Key
锌剂不可或缺：临床应用需结合具体场景
Andi L Shane and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1401–e1402, https://doi.org/10.1093/cid/ciag112
73
When IS900 Positivity is not the Tie-Breaker: Interpreting Mycobacterium avium Subspecies paratuberculosis Signals Across Crohn's Disease and Intestinal Tuberculosis in a Tuberculosis-Endemic Setting
IS900阳性结果不可作为鉴别金标准：结核高发区克罗恩病与肠结核中副结核分枝杆菌判读要点
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1402–e1403, https://doi.org/10.1093/cid/ciag127
74
MAP Detection: Identifying a Pathogenic Driver Rather Than a Diagnostic Marker
副结核分枝杆菌检测：识别致病驱动因素而非单纯诊断标志物
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1403–e1405, https://doi.org/10.1093/cid/ciag128
75
Composite End Points, Minor Anomalies, and Missed Work-Ups: Making 12-Month Infant “Unfavorable Outcomes” Interpretable After BDLLfx/BDLCfz in Pregnancy
复合终点、轻微异常与漏诊评估：解读孕期BDLLfx/BDLCfz方案暴露婴儿12个月不良结局
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1405–e1406, https://doi.org/10.1093/cid/ciag142
76
Responding Appropriately to Safety Signals in Infants Exposed to the 6-month BDLLfx/BDLCfz Regimen In Utero
妥善处置宫内暴露6个月BDLLfx/BDLCfz方案婴儿的安全预警信号
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1406–e1407, https://doi.org/10.1093/cid/ciag143
2026-08-03
·吉玛基因
吉玛基因2026年7月高分文献合集来啦~
6月使用吉玛基因产品发表的SCI文献共475篇。
01
RNA
发表期刊：Autophagy
IF：18.6
文章标题:Porcine reproductive and respiratory syndrome virus hijacks the non-canonical enzymatic function of PHGDH to arrest autophagic flux for viral replication
中文标题:猪繁殖与呼吸综合征病毒劫持 PHGDH 的非经典酶功能，从而阻断自噬流以促进病毒复制
客户单位：中国农业大学兽医学院
吉玛产品：siRNA的靶向序列
研究方向：阻断自噬流以促进病毒复制
发表期刊：Nature Communications
IF：18.1
文章标题:YBX1 Confers immunosuppressive bone metastatic traits in non-small cell lung cancer
中文标题:YBX1赋予非小细胞肺癌骨转移灶免疫抑制特性
客户单位：南京中医药大学
吉玛产品：小干扰RNA（siRNA）
研究方向：赋予非小细胞肺癌骨转移灶免疫抑制特性
发表期刊：Nature Communications
IF：18.1
文章标题:HMGCS1 drives cholesterol-dependent membrane repair and shields tumor cells from lymphocyte attack
中文标题: HMGCS1驱动胆固醇依赖性膜修复，并保护肿瘤细胞免受淋巴细胞攻击
客户单位：中国科学院上海生物化学与细胞生物学研究所
吉玛产品：针对人类CHMP2B、 MVK 、 PMVK 及FDFT1基因的siRNA寡核苷酸
研究方向：保护肿瘤细胞免受淋巴细胞攻击
发表期刊：Nature Communications
IF：18.1
文章标题:Epigenetic compartmentalization of mitotic chromosomes by phase-separation-driven repulsion between WDR5 and the chromosomal passenger complex
中文标题:通过WDR5与染色体乘客复合体之间由相分离驱动的排斥作用实现有丝分裂染色体的表观遗传区室化
客户单位：中国科学技术大学生命科学与医学学院
吉玛产品：siRNA配体/靶向WDR5的siRNA寡核苷酸序列为5‘-gauggauccuugauaguuu-3
研究方向：实现有丝分裂染色体的表观遗传区室化
发表期刊：EXPERIMENTAL AND MOLECULAR MEDICINE
IF：17.5
文章标题:Tumor-derived WNT7A reprograms pulmonary fibroblasts to remodel the metastatic niche and promote bladder cancer lung metastasis
中文标题:肿瘤源性WNT7A可重编程肺成纤维细胞，重塑转移微环境并促进膀胱癌向肺部转移
客户单位：上海同济大学医学院附属同济医院
吉玛产品：短发夹RNA、小干扰RNA（siRNA）、miR-1910-5p模拟物及miR-1910-5p抑制剂，以及WNT7A、MYC和CTDNEP1构建体
研究方向：重塑转移微环境并促进膀胱癌向肺部转移
发表期刊：Acta Pharmaceutica Sinica B
IF：14.6
文章标题:Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β1-mediated endothelial–mesenchymal transition
中文标题: 肝细胞因子FGL1通过整合素 β1 介导的内皮-间质转化途径促进内皮损伤及动脉粥样硬化形成
客户单位：哈尔滨医科大学
吉玛产品：ILK siRNA
研究方向：促进内皮损伤及动脉粥样硬化形成
发表期刊：Acta Pharmaceutica Sinica B
IF：14.6
文章标题: Formicacid released by intratumoral Bacteroides thetaiotaomicron facilitates combinational therapy of Apatinib and aPD-1 in hepatocellular carcinoma
中文标题: 瘤内释放的多形拟杆菌产生的甲酸有助于阿帕替尼与aPD-1联合治疗肝细胞癌
客户单位：上海海军医科大学第三附属医院
吉玛产品：短干扰RNA（siRNA）
研究方向：阿帕替尼与aPD-1联合治疗肝细胞癌
发表期刊：Genes & Diseases
IF：14.6
文章标题:ZO-2 blocks the localization of PGAM5 protein to the mitochondrial membrane and suppresses pancreatic cancer malignancy through metabolic reprogramming
中文标题:ZO-2可阻断PGAM5蛋白在线粒体膜上的定位，并通过代谢重编程抑制胰腺癌的恶性进展
客户单位：华南理工大学医学院
吉玛产品：针对不同 mRNA 的 siRNA 序列
研究方向：通过代谢重编程抑制胰腺癌的恶性进展
发表期刊：Advanced Science
IF：14.1
文章标题:Genome-Wide In Vivo RNAi Screening Identifies HOXD4 as a Tumor Metastasis Suppressor in Colorectal Cancer
中文标题:全基因组体内RNA干扰筛选证实HOXD4是结直肠癌中的肿瘤转移抑制因子
客户单位：中山大学肿瘤防治中心
吉玛产品：SiRNAs
研究方向：证实HOXD4是结直肠癌中的肿瘤转移抑制因子
发表期刊：Advanced Science
IF：14.1
文章标题: Wavelength-Dependent Photobiomodulation Regulates Macrophage Polarization via Mitochondrial Dynamics and Metabolic Reprogramming
中文标题:波长依赖性光生物调节通过线粒体动力学与代谢重编程调控巨噬细胞极化
客户单位：1 北京航空航天大学生物力学与机械生物学重点实验室，北京航空航天大学生物医学工程高级创新中心，生物科学与医学工程学院2 苏州大学未来科学与工程学院
吉玛产品：靶向MFN1和MFN2的siRNA
研究方向：线粒体动力学与代谢重编程调控巨噬细胞极化
发表期刊：Advanced Science
IF：14.1
文章标题: Targeting Lactate-Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD-1 Blockade
中文标题:通过MCT1靶向乳酸驱动的基质自噬可破坏免疫抑制微环境并增强胰腺癌对PD-1阻断疗法的敏感性
客户单位：华中科技大学同济医学院附属联合医院
吉玛产品：特异性siRNA与随机序列siRNA
研究方向：破坏免疫抑制微环境并增强胰腺癌对PD-1阻断疗法的敏感性
发表期刊：Advanced Science
IF：14.1
文章标题:The E3 Ligase RNF115 Aggravates Pathological Cardiac Hypertrophy via Ubiquitin-Mediated Degradation of SPTBN1
中文标题:E3连接酶RNF115通过泛素介导的SPTBN1降解加剧病理性心肌肥厚
客户单位：南京医科大学
吉玛产品：小干扰RNA
研究方向：降解加剧病理性心肌肥厚
发表期刊：Advanced Science
IF：14.1
文章标题: HLA-DR+ Schwann Cells Generate the Protumor Cancer-Neuron-Immune Niche in Head and Neck Squamous Cell Carcinoma
中文标题:HLA-DR阳性施万细胞在头颈部鳞状细胞癌中形成促肿瘤的癌-神经元-免疫微环境
客户单位：上海第九人民医院
吉玛产品：针对NRG1和 CIITA 的特异性siRNA
研究方向：在头颈部鳞状细胞癌中形成促肿瘤的癌-神经元-免疫微环境
发表期刊：Advanced Science
IF：14.1
文章标题:Ultrasound-Activatable Piezoelectric Hydrogel Reprograms Mitochondrial Epigenetics for Osteoarthritis Therapy via the mTOR/GATD3A Axis
中文标题:超声激活压电水凝胶通过mTOR/GATD3A轴重编程线粒体表观遗传学以治疗骨关节炎
客户单位：湖南大学材料科学与工程学院
吉玛产品：siRNA 序列
研究方向：轴重编程线粒体表观遗传学以治疗骨关节炎
发表期刊：Advanced Science
IF：14.1
文章标题:Pericentrosomal Redistribution of the Endoplasmic Reticulum Ensures Organelle Symmetric Inheritance and Mitotic Progression
中文标题:内质网的中心体周围重新分布确保细胞器对称遗传及有丝分裂进程
客户单位：北京大学生命科学学院
吉玛产品：siRNAs
研究方向：确保细胞器对称遗传及有丝分裂进程
发表期刊：Advanced Science
IF：14.1
文章标题: ZER1 Restrains Pressure Overload-Induced Cardiac Remodeling by Targeting DVL2 for Gly/N-Degron-Dependent Degradation
中文标题:ZER1通过靶向DVL2介导其甘氨酸/N-Degron依赖性降解，从而抑制压力超负荷诱导的心脏重构
客户单位：温州医科大学
吉玛产品：siRNAs
研究方向：抑制压力超负荷诱导的心脏重构
发表期刊：Advanced Science
IF：14.1
文章标题:Integrative Omics Analysis Reveals the Regulation of Hypoxia Tolerance in Large Yellow Croaker (Larimichthys crocea) via the Lipoic Acid Synthase (lias) Gene
中文标题:整合组学分析揭示了大黄鱼（Larimichthys crocea）中缺氧耐受性的调控机制与硫辛酸合酶（Lias）基因的关系
客户单位：宁波大学海洋科学学院
吉玛产品：靶向Lias蛋白的小干扰RNA（siRNA）
研究方向：缺氧耐受性的调控机制与硫辛酸合酶（Lias）基因的关系
发表期刊：Cell Reports Medicine
IF：14
文章标题:Commensal Cutibacterium acnes-derived indolelactic acid safeguards skin barrier function through the aryl hydrocarbon receptor
中文标题: 共生菌痤疮皮肤杆菌来源的吲哚乳酸通过芳烃受体保护皮肤屏障功能
客户单位：中国医学科学院皮肤科学研究所
吉玛产品：siRNA
研究方向：通过芳烃受体保护皮肤屏障功能
发表期刊：Molecular Biomedicine
IF：13
文章标题:TELO2-interacting protein 1 (TTI1), a novel Wnt/β-catenin target gene, decreases chemo-sensitivity in colorectal cancer by modulating DNA damage responses
中文标题: TELO2相互作用蛋白1（TTI1）作为新型Wnt/ β -连环蛋白靶基因，通过调控DNA损伤应答来降低结直肠癌的化疗敏感性
客户单位：湖南中南大学湘雅医院
吉玛产品：β -连环蛋白及TTI1 siRNA
研究方向：通过调控DNA损伤应答来降低结直肠癌的化疗敏感性
发表期刊：PHARMACOLOGICAL RESEARCH
IF：12.2
文章标题:Microglial OTUD6A promotes neuroinflammation and Alzheimer’s disease pathogenesis by deubiquitinating C/EBPβ
中文标题: 小胶质细胞中的OTUD6A通过去泛素化C/ EBPβ 蛋白，促进神经炎症反应及阿尔茨海默病的发病机制
客户单位：杭州市临安区第一人民医院
吉玛产品：靶向OTUD6A和C/ EBPβ 的siRNA
研究方向：促进神经炎症反应及阿尔茨海默病的发病机制
发表期刊：Cell Death & Disease
IF：12.2
文章标题:MMP7-Triggered mitophagy by regulating parkin-mediated ubiquitination of VDAC1 confers anoikis resistance in the epithelium of hyperplastic prostate
中文标题: MMP7通过调控Parkin介导的VDAC1泛素化来触发线粒体自噬，从而赋予增生性前列腺上皮细胞抗失巢凋亡能力
客户单位：企业订阅用户中南医院
吉玛产品：siMMP7、siHSPA1A 和 siJUN
研究方向：赋予增生性前列腺上皮细胞抗失巢凋亡能力
发表期刊：Cell Death & Disease
IF：12.2
文章标题:Cdk1-phosphorylated Nur77 accumulates at the centrosome during mitosis to regulate the Cep192–PLK1 signaling axis
中文标题: Cdk1磷酸化的Nur77在有丝分裂期间积聚于中心体，以调控Cep192–PLK1信号轴
客户单位：厦门大学药学院
吉玛产品：Cep192 siRNA（5‘-ggaagacauuuucaucucu-3’）及PLK1 siRNA（5‘-ccuugaugaagaagaucac-3）/对照siRNA
研究方向：调控Cep192–PLK1信号轴
发表期刊：Cell Death & Disease
IF：12.2
文章标题:TSC22D4 drives clear cell renal cell carcinoma progression and therapy resistance by stabilizing NRF2 through KEAP1 disruption
中文标题: TSC22D4通过破坏KEAP1来稳定NRF2，从而促进透明细胞肾细胞癌的进展并增强其治疗耐药性
客户单位：上海海军医科大学长征医院
吉玛产品：阴性对照siRNA以及靶向TSC22D4和KEAP1的特异性siRNA
研究方向：促进透明细胞肾细胞癌的进展并增强其治疗耐药性
发表期刊：Cell Death & Disease
IF：12.2
文章标题:Pictilisib and nutrient stress synergize to induce methuosis via PI(4,5)P2-dependent macropinocytic dysregulation in cancer cells
中文标题: 皮替利司与营养应激协同作用，通过PI(4,5)P2依赖性巨胞饮调节异常在癌细胞中诱导甲硫氨酸合成酶活性。
客户单位：中国辽宁省大连市大连医科大学
吉玛产品：siRNA试剂
研究方向：依赖性巨胞饮调节异常在癌细胞中诱导甲硫氨酸合成酶活性
发表期刊：Cell Death & Disease
IF：12.2
文章标题:The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication
中文标题: CDK4/6抑制剂达利西利通过抑制MCM4介导的DNA复制，在去势抵抗性前列腺癌的临床前模型中增强了恩杂鲁胺的抗肿瘤疗效
客户单位：企业订阅用户中南医院
吉玛产品：靶向CDK4、CDK6和AR的小干扰RNA（siRNA）
研究方向：在去势抵抗性前列腺癌的临床前模型中增强了恩杂鲁胺的抗肿瘤疗效
发表期刊：Cell Death & Disease
IF：12.2
文章标题:EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer
中文标题: 癌干细胞通过 EGFR 依赖性方式递送磷酸化IGFBP3，从而驱动结直肠癌的化疗耐药性
客户单位：上海医科大学附属浦东公利医院
吉玛产品：携带荧光素酶的慢病毒
研究方向：驱动结直肠癌的化疗耐药性
发表期刊：Cell Death & Disease
IF：12.2
文章标题:Astrocytic SCAP deletion ameliorates diabetes-associated cognitive impairment by suppressing microglial neuroinflammation and lipid droplet accumulation via the LCN2–24p3R–mTOR axis
中文标题: 星形胶质细胞 SCAP 缺失可通过LCN2–24p3R–mTOR通路抑制小胶质细胞神经炎症及脂滴积聚，从而改善糖尿病相关的认知功能障碍
客户单位：南京东南大学附属中大医院内分泌科
吉玛产品：SCAP 过表达质粒（pcDNA3.1- SCAP）及相应的空载体对照（pcDNA3.1-NC）/ siRNAs
研究方向：通路抑制小胶质细胞神经炎症及脂滴积聚，从而改善糖尿病相关的认知功能障碍
发表期刊：Journal for ImmunoTherapy of Cancer
IF：11.7
文章标题:USP1-mediated lipophagy-lipogenesis axis drives cholangiocarcinoma progression and immune evasion
中文标题: USP1介导的脂噬作用-脂生成轴驱动胆管癌进展及免疫逃逸
客户单位：上海医科大学附属浦东公利医院
吉玛产品：针对 NRC的特异性 siRNA/序列：5’-CCCAGGUA AAGAGACGAAUTT-3’）以及针对PPP1CB的特异性siRNA
研究方向：脂生成轴驱动胆管癌进展及免疫逃逸
发表期刊：Journal for ImmunoTherapy of Cancer
IF：11.7
文章标题:Lithocholic acid-activated VDR in macrophages promotes HCC recurrence post-ablation via SOCS3-mediated suppression of CXCL16
中文标题: 巨噬细胞中经石胆酸激活的维生素D受体（VDR）通过SOCS3介导的CXCL16抑制作用，促进消融术后 HCC 复发
客户单位：广东省广州市中山纪念医院超声科
吉玛产品：针对小鼠特异性VDR的siRNA/靶向小鼠特异性Socs的siRNA
研究方向：通过SOCS3介导的CXCL16抑制作用，促进消融术后 HCC 复发
发表期刊：Journal for ImmunoTherapy of Cancer
IF：11.7
文章标题:Dexamethasone activates anti-tumor immunity in multiple myeloma by dismantling the GR-PPP1CB complex to restore STING/IRF3 signaling
中文标题: 地塞米松通过解离GR-PPP1CB复合体来恢复sting/IRF3信号通路，从而激活多发性骨髓瘤中的抗肿瘤免疫反应。
客户单位：南京中医药大学附属南京中医医院
吉玛产品：针对 NRC的特异性 siRNA/序列：5’-CCCAGGUA AAGAGACGAAUTT-3’）以及针对PPP1CB的特异性siRNA
研究方向：激活多发性骨髓瘤中的抗肿瘤免疫反应
发表期刊：Cell Communication and Signaling
IF：11.6
文章标题:Heterodimerization with signaling-inert TLR8b converts TLR8a from proviral to antiviral sensor in Ctenopharyngodon idella
中文标题: 与信号传导惰性TLR8b发生异源二聚化可使TLR8a在Ctenopharyngodon idella中从前病毒传感器转变为抗病毒传感器
客户单位：华中农业大学渔业学院
吉玛产品：生物素-ssRNA (5′-BiotinGsCsCsCsGsUsCsUsGsUsUsGsUsGsUsGsAsCsUsC-3‘，中的“s”表示磷酸硫酯键/CiM D88与CiTIRAP在体外实验中的表现，以及18种siRNA序列/阴性对照siRNA
研究方向：在Ctenopharyngodon idella中从前病毒传感器转变为抗病毒传感器
发表期刊：Cell Death Discovery
IF：10.4
文章标题:Deficiency of LIMA1 accelerates bladder cancer progression by disrupting PINK1/Parkin-mediated mitophagy
中文标题: LIMA1缺陷通过破坏PINK1/Parkin介导的线粒体自噬加速膀胱癌进展
客户单位：南京医科大学
吉玛产品：siLIMA1以及作为对照的随机序列siRNA
研究方向：线粒体自噬加速膀胱癌进展
发表期刊：Cell Death Discovery
IF：10.4
文章标题:GPR84 aggravates lung inflammation through activating ZBP1-PANoptosome mediated PANoptosis following IAV infection
中文标题: GPR84通过激活 IAV 感染后由ZBP1-PANoptosome介导的PANoptosis，加剧肺部炎症反应
客户单位：成都中医药大学基础医学院
吉玛产品：siRNA Mate Plus
研究方向：由ZBP1-PANoptosome介导的PANoptosis，加剧肺部炎症反应
发表期刊：Cell Death Discovery
IF：10.4
文章标题:HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy
中文标题: HAAO 衍生的喹啉酸可激活 FDPS 依赖性雄激素受体信号通路，并增强前列腺癌对联合治疗的敏感性
客户单位：中国科学院北京生命科学研究院
吉玛产品：siRNAs
研究方向：增强前列腺癌对联合治疗的敏感性
发表期刊：Cell Death Discovery
IF：10.4
文章标题:The role and mechanism of tubulin folding cofactor B in glioblastoma migration
中文标题: 微管蛋白折叠辅助因子B在胶质母细胞瘤迁移中的作用与机制
客户单位：重庆医科大学神经科学研究所
吉玛产品：siRNAs
研究方向：B在胶质母细胞瘤迁移中的作用与机制
02
全基因
发表期刊：Nature Communications
IF：18.1
文章标题:Targeting the Ip6k2–Runx2 axis disrupts osteoblast–osteoclast coupling to treat osteoporosis
中文标题:靶向Ip6k2–Runx2轴可破坏成骨细胞与破骨细胞的耦联关系，从而治疗骨质疏松症
客户单位：深圳市南方科技大学医学院
吉玛产品：双荧光素酶报告基因检测系统
研究方向：治疗骨质疏松症
发表期刊：Genes & Diseases
IF：14.6
文章标题:Targeting TMEM45A, a regulator of endoplasmic reticulum stress, inhibits tumor growth and enhances 5-FU sensitivity in gastric and cervical cancer
中文标题:靶向TMEM45A（内质网应激的调节因子）可抑制胃癌和宫颈癌的肿瘤生长并增强其对5-氟尿嘧啶（5-FU）的敏感性
客户单位：南通大学附属医院检验医学科
吉玛产品：获得了TMEM45A（sh-TMEM45A）、TMEM45A过表达载体（pc-TMEM45A）、CAMP反应元件结合蛋白3样蛋白1（CREB3L1）过表达载体（pc-CREB3L1）及其相应的对照构建体（sh-NC和空载体）/双荧光素酶报告基因检测系统
研究方向：抑制胃癌和宫颈癌的肿瘤生长并增强其对5-氟尿嘧啶（5-FU）的敏感性
发表期刊：Advanced Science
IF：14.1
文章标题:Radiation-Induced Tumor-Intrinsic LTβR N-Glycosylation Suppresses Pyroptosis Through TRIM28-Mediated PCBP2 SUMOylation to Promote Gastric Cancer Radioresistance
中文标题:辐射诱导的肿瘤内在 LTβR N-糖基化通过TRIM28介导的PCBP2SUMO化抑制焦亡，从而增强胃癌的放射抵抗性
客户单位：南通大学医学院附属医院消化外科
吉玛产品：Flag- LTβR 、HA-PCBP2（野生型/K37R突变体）及His-TRIM28（野生型/C651A突变体）的表达质粒
研究方向：增强胃癌的放射抵抗性
发表期刊：Advanced Science
IF：14.1
文章标题:Stiffness-Activated Stellate Cells Drive Pancreatic Cancer Liver Colonization via GMFG-TNS4 Signaling
中文标题:刚度激活的星形细胞通过 GMFG -TNS4信号通路驱动胰腺癌在肝脏定植
客户单位：南通大学附属医院及医学院
吉玛产品：带有Flag标签的 GMFG 过表达质粒与带有HA标签的TNS4过表达质粒
研究方向：信号通路驱动胰腺癌在肝脏定植
发表期刊：Advanced Science
IF：14.1
文章标题: Targeting WDR12 Unleashes T-Cell-Mediated Antitumor Activity in Melanoma by Destabilizing CD276
中文标题:靶向WDR12通过 destabilize CD276释放T细胞介导的黑色素瘤抗肿瘤活性
客户单位：中南大学湘雅医院皮肤科
吉玛产品：靶向小鼠Wdr12的短发夹RNA（shRNA）
研究方向：释放T细胞介导的黑色素瘤抗肿瘤活性
发表期刊：Cell Communication and Signaling
IF：11.6
文章标题:NANOS3-YTHDF2 drives aberrant P-body accumulation to impair folliculogenesis in offspring of maternal aristolochic acid I exposure
中文标题: NANOS3-YTHDF2驱动异常P体积聚，从而损害母体接触马兜铃酸I后子代的卵泡发育
客户单位：重庆医科大学基础医学院
吉玛产品：含有三个全长编码序列的质粒
研究方向：损害母体接触马兜铃酸I后子代的卵泡发育
发表期刊：Materials Today Bio
IF：11
文章标题:Biomimetic cellular sponges for neutralizing inflammatory cytokines in osteoarthritic joints
中文标题: 仿生细胞海绵用于中和骨关节炎关节中的炎症细胞因子
客户单位：苏州大学第一附属医院骨科
吉玛产品：IL1R2/TNFR2穿梭质粒载体
研究方向：骨关节炎关节中的炎症细胞因子
发表期刊：Cell Death Discovery
IF：10.4
文章标题:GATA1 repression-mediated ADRB2/cAMP/PKA signaling activation underlies the antidepressant effects of targeted geniposide delivery
中文标题: 通过GATA1抑制介导的ADRB2/cAMP/ PKA 信号通路激活，是靶向姜黄素递送发挥抗抑郁作用的基础机制
客户单位：重庆医科大学
吉玛产品：控制质粒或GATA1过表达质粒/ADRB 启动子/GATA1过表达质粒
研究方向：靶向姜黄素递送发挥抗抑郁作用的基础机制
03
FISH 或 试剂盒&引物探针套装
发表期刊：Journal of Advanced Research
IF：17.1
文章标题:PAD4-mediated citrullination of IGF2BP2 stabilizes MCM mRNAs to drive intrahepatic cholangiocarcinoma progression
中文标题:PAD4介导的IGF2BP2瓜氨酸化可稳定MCM mRNA，从而促进肝内胆管癌进展
客户单位：中国药科大学基础医学与临床药学院
吉玛产品：生物素标记的MCM2-3′ UTR 和MCM7-3′ UTR 探针
研究方向：稳定MCM mRNA，从而促进肝内胆管癌进展
发表期刊：Genes & Diseases
IF：14.6
文章标题:Fusobacterium nucleatum-mediated tryptophan metabolic reprogramming facilitates immunosuppression and metastasis in triple-negative breast cancer
中文标题:核梭杆菌介导的色氨酸代谢重编程促进三阴性乳腺癌的免疫抑制与转移
客户单位：重庆医科大学
吉玛产品：FISH探针及FISH试剂盒
研究方向：促进三阴性乳腺癌的免疫抑制与转移
发表期刊：JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
IF：14.3
文章标题:Inhibition of 5’-tiRNAGly restores anti-PD-1 immunotherapy efficacy via DLST-mediated OGDHL succinylation in gastric cancer
中文标题:抑制5‘-tiRNAGly可通过 DLST 介导的 OGDHL 琥珀酰化作用恢复胃癌中抗PD-1免疫疗法的疗效
客户单位：南通大学医学院附属医院
吉玛产品：tiRNAGly探针
研究方向：恢复胃癌中抗PD-1免疫疗法的疗效
发表期刊：Journal of Pharmaceutical Analysis
IF：11.2
文章标题:Sculponeatin A promotes SMURF1-mediated KLF5 degradation and disrupts KLF5/c-Myc co-liquid-liquid phase separation to inhibit aerobic glycolysis in gastric cancer
中文标题: Sculponeatin A可促进SMURF1介导的KLF5降解，并破坏KLF5/c-Myc共液-液相分离，从而抑制胃癌中的有氧糖酵解
客户单位：湖北医科大学基础医学研究所
吉玛产品：针对HK2和228 LDHA 的Cy5标记探针
研究方向：抑制胃癌中的有氧糖酵解
04
病毒
发表期刊：Genes & Diseases
IF：14.6
文章标题:Enhanced generation of new neurons from activated endogenous neural stem cells by PTBP1 knockdown following spinal cord injury
中文标题:脊髓损伤后通过PTBP1基因敲低促进活化内源性神经干细胞生成新神经元
客户单位：北京老年医学研究所
吉玛产品：LV3（H1/ GFP &Puro）-PTBP1慢病毒载体
研究方向：促进活化内源性神经干细胞生成新神经元
发表期刊：Cell Reports Medicine
IF：14
文章标题:Self-assembly of tumor-related vascularized colorectal tumoroid-on-a-chip for precision medicine drug testing
中文标题: 肿瘤相关血管化结直肠类瘤芯片的自组装用于精准医学药物测试
客户单位：南京大学医学院附属金陵医院
吉玛产品：LV5（EF- 1α / GFP 及Puro系列）/LV8N（EF- 1α /mCherry与Puro标记）/用于HUVECs感染的慢病毒/慢病毒
研究方向：精准医学药物测试
发表期刊：Research
IF：12.9
文章标题:M2 Macrophages Attenuate AQP2⁺ Collecting Duct Cell Apoptosis via the TRAF1–TRAF2 Complex to Suppress Randall's Plaque Formation
中文标题: M2型巨噬细胞通过TRAF1–TRAF2复合体抑制AQP2阳性集合管细胞凋亡，从而阻止Randall斑块形成
客户单位：中南大学湘雅医院泌尿外科
吉玛产品：重组慢病毒
研究方向：阻止Randall斑块形成
发表期刊：Cell Death & Disease
IF：12.2
文章标题:Vascular SMC-like CAF-derived THBS1 drives tumor-associated neutrophil recruitment to orchestrate an immunosuppressive microenvironment in gastric cancer
中文标题: 血管平滑肌细胞样癌相关成纤维细胞来源的THBS1驱动肿瘤相关中性粒细胞募集，从而调控胃癌中的免疫抑制微环境
客户单位：湖北医科大学太和医院
吉玛产品：在细胞敲除实验中，CAF细胞被转导了靶向THBS1的慢病毒
研究方向：调控胃癌中的免疫抑制微环
发表期刊：Cell Death Discovery
IF：10.4
文章标题:NRP1 promotes hepatic fibrosis by regulating Src/Rab7-mediated lysosomal degradation of TβRI
中文标题: NRP1通过调控Src / Rab7介导的 TβRI 溶酶体降解过程而促进肝纤维化
客户单位：北京友谊医院普外科
吉玛产品：为实现造血干细胞（HSC）特异性基因沉默，需通过单次尾静脉注射腺相关病毒（AAV）-pLrat-shNrp1载体
研究方向：促进肝纤维化
05
RNA 和 转染试剂
发表期刊：Advanced Science
IF：14.1
文章标题:GPR124 Alleviates Blood–Brain Barrier Disruption by Enhancing Microvascular Endothelial Function after Traumatic Brain Injury
中文标题:GPR124通过增强创伤性脑损伤后的微血管内皮功能缓解血脑屏障破坏
客户单位：上海交通大学医学院附属第六人民医院
吉玛产品：si-GPR124与对照siRNA
研究方向：微血管内皮功能缓解血脑屏障破坏
06
全基因 和 RNA
发表期刊：Advanced Science
IF：14.1
文章标题:CEBPG-Mediated Palmitic Acid Adaptation of Cancer-Associated Fibroblasts Drives Metastasis of Oral Squamous Cell Carcinoma
中文标题:CEBPG 介导的癌相关成纤维细胞棕榈酸适应性改变驱动口腔鳞状细胞癌转移
客户单位：企业订阅用户口腔医学院及附属医院
吉玛产品：编码 CEBPG 的质粒（pcDNA3.1- CEBPG）、以及靶向 CEBPG 、ERN1和TMBIM6的siRNA（体外及体内实验中使用）/siRNA-mate plus/抑制效应
研究方向：改变驱动口腔鳞状细胞癌转移
07
RNA 或 蛋白
发表期刊：Advanced Science
IF：14.1
文章标题:RNA-Binding Protein RBM25 Targets the mRNA Stability of GTPase Rab22a to Restrict Viral Entry and Infection
中文标题:RNA结合蛋白RBM25通过影响GTP酶Rab22a的mRNA稳定性来限制病毒入侵与感染
客户单位：上海海军医科大学病原生物学系
吉玛产品：靶向小鼠Rab22a的特异性siRNA寡核苷酸/靶向小鼠Rc3h1的特异性siRNA寡核苷酸
研究方向：限制病毒入侵与感染
08
蛋白
发表期刊：Advanced Science
IF：14.1
文章标题:Targeting the HSPA8-CMA-ATP6V1A Axis Triggers Lysosomal Hyperacidification and Catastrophic Vacuolation in Prostate Cancer
中文标题:靶向HSPA8-CMA-ATP6V1A轴可引发前列腺癌中的溶酶体过度酸化及严重空泡化
客户单位：山东大学齐鲁医院泌尿外科
吉玛产品：所有基因特异性引物
研究方向：前列腺癌中的溶酶体过度酸化及严重空泡化
09
转染试剂
发表期刊：npj Aging
IF：13
文章标题:LncRNA Lncbate1 promotes lipid synthesis in the white adipose tissue during aging by targeting the miR-455-5p―ACSS1 axis
中文标题: 长链非编码RNA Lncbate1通过靶向miR-455-5p–ACSS1轴，在衰老过程中促进白色脂肪组织中的脂质合成
客户单位：湖北中医药大学基础医学学院
吉玛产品：转染过程采用了miR-455-5p抑制剂、miR-455-5p模拟物以及siLncbate1
研究方向：在衰老过程中促进白色脂肪组织中的脂质合成
发表期刊：PHYTOMEDICINE
IF：11.3
文章标题:Panax notoginseng saponins attenuate glomerular endothelial glycocalyx degradation in diabetic nephropathy
中文标题: 三七皂苷可减轻糖尿病肾病中肾小球内皮糖萼的降解
客户单位：上海海洋大学渔业与生命科学学院
吉玛产品：为实现HPSE1基因敲降，研究人员使用小鼠HPSE1小干扰RNA对MRGEC细胞进行了转染/为实现HPSE1的过表达，研究人员使用编码HPSE1的重组慢病毒以200的感染复数对MRGEC细胞进行感染
研究方向：减轻糖尿病肾病中肾小球内皮糖萼的降解
10
DNA(蛋白质)
发表期刊：Materials Today Bio
IF：11
文章标题:P2-engineered exosomes encapsulating curcumin alleviate cognitive decline in AD-like mice by improving microglia-related neuropathology
中文标题: 封装姜黄素的P2工程化外泌体通过改善小胶质细胞相关神经病理学改变，缓解阿尔茨海默病样小鼠的认知功能衰退
客户单位：贵州医科大学
吉玛产品：P2-Lamp2b融合基因
研究方向：缓解阿尔茨海默病样小鼠的认知功能衰退
11
全基因 或 转染试剂
发表期刊：JOURNAL OF HAZARDOUS MATERIALS
IF：10.6
文章标题:HFPO-TA inhibits testosterone synthesis by triggering FTO-mediated m6A modification to drive NCOA4-associated ferroptosis
中文标题: HFPO - TA通过触发 FTO 介导的m6A修饰来抑制睾酮合成，从而驱动NCOA4相关的铁死亡
客户单位：宁夏医科大学
吉玛产品：GP转染细胞株/质粒
研究方向：驱动NCOA4相关的铁死亡
12
RNA 和 试剂盒&引物探针套装 或 转染试剂
发表期刊：ENVIRONMENT INTERNATIONAL
IF：10.2
文章标题: Integrated network toxicology and transcriptomics reveal NF-κB signaling as a key mediator of TDCPP-induced inflammatory responses in human microglia
中文标题: 整合网络毒理学与转录组学研究揭示， NF - κB 信号通路是 TDCPP 诱导的人类小胶质细胞炎症反应的关键介导因子
客户单位： 杭州医学院公共卫生学院
吉玛产品：siRNA与转染试剂/siRNA-Mate Plus转染试剂盒
研究方向：NF - κB 信号通路是 TDCPP 诱导的人类小胶质细胞炎症反应的关键介导因子
关于吉玛基因
吉玛基因（NEEQ:430601）作为中国小核酸产业全链条技术服务商，自2003年由张佩琢博士带领海归团队创立以来，以RNAi技术为核心，构建了从 RNA 单体合成到新药研发的完整产业链。公司通过ISO9001与ISO13485质量体系认证，截至2025年底，累计SCI文献引用超80000篇，服务全球 7000多家合作伙伴，授权专利71项，是国内核酸科研服务与小核酸药物开发领域的领先品牌。
公司构建了覆盖“科研服务—成果转化—产业开发”的全链条服务能力。
§ 在科研端，提供RNA合成、基因编辑、病毒包装、动物模型等RNA研究全领域一站式解决方案；
§ 在转化端，与全国高校生物医药区域技术转移转化中心和中科苏州药物研究院深度合作，为高校及科研院所提供从概念验证到PCC确认的科技成果转化服务，并配套资金支持，助力创新成果高效向药企转让；
§ 在产业端，为药企提供小核酸药物临床前一站式开发与生产全流程支持，与国家生物药技术创新中心共建核酸药物GMP中试生产平台，具备AI辅助设计、肝外递送等核心技术，可满足IND申报与临床Ⅰ-Ⅱ期样品生产需求。已成功交付10余个PCC分子，含BIC/FIC项目。
全国免费咨询电话：400-690-0195
官网: www.genepharma.com
联系我们
苏州吉玛基因股份有限公司
地址：苏州工业园区东平街199号
邮箱：szorder@genepharma.com
电话：0512-86668828
上海吉玛制药技术有限公司
地址：上海浦东新区张江路368号2号楼
邮箱：order@genepharma.com
电话：021-51320195
赶紧关注我们吧~
siRNA临床1期核酸药物寡核苷酸
100 项与 地塞米松磷酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑水肿 | 奥地利 | 2021-04-28 | |
| 脑水肿 | 比利时 | 2021-04-28 | |
| 脑水肿 | 保加利亚 | 2021-04-28 | |
| 脑水肿 | 克罗地亚 | 2021-04-28 | |
| 脑水肿 | 捷克 | 2021-04-28 | |
| 脑水肿 | 丹麦 | 2021-04-28 | |
| 脑水肿 | 芬兰 | 2021-04-28 | |
| 脑水肿 | 德国 | 2021-04-28 | |
| 脑水肿 | 匈牙利 | 2021-04-28 | |
| 脑水肿 | 冰岛 | 2021-04-28 | |
| 脑水肿 | 爱尔兰 | 2021-04-28 | |
| 脑水肿 | 意大利 | 2021-04-28 | |
| 脑水肿 | 荷兰 | 2021-04-28 | |
| 脑水肿 | 挪威 | 2021-04-28 | |
| 脑水肿 | 波兰 | 2021-04-28 | |
| 脑水肿 | 葡萄牙 | 2021-04-28 | |
| 脑水肿 | 罗马尼亚 | 2021-04-28 | |
| 脑水肿 | 斯洛伐克 | 2021-04-28 | |
| 脑水肿 | 斯洛文尼亚 | 2021-04-28 | |
| 新型冠状病毒感染 | 奥地利 | 2021-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 美国 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 美国 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 澳大利亚 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 澳大利亚 | 2019-11-26 | |
| 根性疼痛 | 临床3期 | 美国 | 2017-12-08 | |
| 神经根病 | 临床3期 | 美国 | 2017-12-08 | |
| 共济失调毛细血管扩张 | 临床3期 | 美国 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 澳大利亚 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 比利时 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 德国 | 2017-03-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床4期 | - | 438 | (Group 1) | 鹽範選願壓網鹽夢鏇觸(窪製衊願構鹽醖襯簾蓋) = 遞築鑰範襯憲艱觸鏇醖 壓獵鬱選選簾艱窪獵廠 (觸糧鬱獵積鬱鑰壓範遞, 168.9) 更多 | - | 2026-08-03 | |
鹽範選願壓網鹽夢鏇觸(窪製衊願構鹽醖襯簾蓋) = 範網選構網選餘鬱製廠 壓獵鬱選選簾艱窪獵廠 (觸糧鬱獵積鬱鑰壓範遞, 122.3) 更多 | |||||||
临床4期 | 126 | (IV Dexmethsone and Oral Placebo) | 鏇廠製憲鏇襯鏇簾夢願 = 鑰壓蓋糧醖鹽蓋獵糧願 積艱顧膚衊鹹鑰鹽獵窪 (範壓憲構鑰願鑰憲網糧, 蓋觸鏇選夢願夢憲齋糧 ~ 膚齋製艱遞觸衊壓鑰積) 更多 | - | 2026-07-29 | ||
(Oral Dexamethasone and IV Placebo) | 鏇廠製憲鏇襯鏇簾夢願 = 壓構鏇簾積餘衊鏇餘衊 積艱顧膚衊鹹鑰鹽獵窪 (範壓憲構鑰願鑰憲網糧, 衊繭鏇觸鹽選願構網鹹 ~ 築艱糧構齋廠範願觸繭) 更多 | ||||||
临床2期 | 56 | (No Prior Chemo or Responded/Stable With Prior Chemo) | 窪選鬱顧鏇繭簾鏇顧繭 = 願衊夢觸遞淵顧壓糧製 衊觸顧選觸鏇壓壓遞衊 (鑰築襯網鏇膚糧積構醖, 鬱鑰襯獵鏇夢衊衊積鬱 ~ 獵製網獵遞糧蓋艱繭鏇) 更多 | - | 2026-07-01 | ||
(Patients Who Have Failed Systemic Therapy) | 憲網糧觸淵襯襯選遞廠 = 蓋製糧範選齋構鹹壓築 築糧願網範繭觸糧鏇範 (廠襯遞夢鹽製顧衊襯網, 衊積製選鹽獵衊衊鹽餘 ~ 鏇窪壓憲膚糧獵醖顧壓) 更多 | ||||||
临床2期 | 5 | 壓廠淵範鏇繭壓鬱積鏇 = 觸糧鬱壓淵襯淵鑰築簾 鑰顧鑰簾憲顧壓衊繭餘 (鑰網簾淵構憲範衊廠襯, 艱衊鏇獵鹽網構遞繭鹹 ~ 衊選獵鑰鹽齋選鏇鏇齋) 更多 | - | 2026-06-25 | |||
临床4期 | 120 | (Anesthetic Without Steroid Group) | 簾餘選襯鹽鏇網積鬱蓋(壓壓鹹醖範壓鑰餘範餘) = 築艱積衊糧鹽鑰夢齋憲 鹹膚網獵壓鬱壓齋憲廠 (廠蓋鹹願膚觸築衊顧鬱, 2.2) 更多 | - | 2026-06-24 | ||
(Anesthetic With Dexamethasone Group) | 簾餘選襯鹽鏇網積鬱蓋(壓壓鹹醖範壓鑰餘範餘) = 糧餘獵鹽蓋餘繭醖製艱 鹹膚網獵壓鬱壓齋憲廠 (廠蓋鹹願膚觸築衊顧鬱, 2.3) 更多 | ||||||
临床3期 | 90 | (Conventional) | 遞製觸膚構範廠蓋醖餘 = 簾夢遞遞淵襯醖壓願蓋 齋憲鬱製製遞築憲窪膚 (糧廠糧蓋夢遞憲艱鹽築, 製廠繭繭壓憲襯遞願製 ~ 鏇廠積鹽積廠築襯簾夢) 更多 | - | 2026-06-09 | ||
(Short-Course) | 遞製觸膚構範廠蓋醖餘 = 鏇築願衊壓觸遞鏇廠積 齋憲鬱製製遞築憲窪膚 (糧廠糧蓋夢遞憲艱鹽築, 衊鹽壓餘窪蓋窪衊蓋鏇 ~ 遞鬱膚築艱糧鏇遞繭淵) 更多 | ||||||
临床3期 | 1,850 | 鹽窪積觸齋襯積壓膚鏇(顧窪餘窪鬱簾範繭製網) = 鹹廠網衊鏇淵餘繭蓋鑰 網憲鏇簾鹽築網蓋積積 (蓋襯積網蓋積壓膚製積 ) | 积极 | 2026-06-05 | |||
鹽窪積觸齋襯積壓膚鏇(顧窪餘窪鬱簾範繭製網) = 窪襯窪襯積糧窪築鏇觸 網憲鏇簾鹽築網蓋積積 (蓋襯積網蓋積壓膚製積 ) | |||||||
临床1/2期 | 多发性骨髓瘤 一线 | 36 | 願壓鹹製壓餘醖網壓餘(繭蓋壓製範鹽鹽選構襯) = 構鬱衊簾膚顧衊艱願鹹 網醖齋淵淵糧淵願鑰構 (鬱鑰淵選簾簾顧憲鹹鏇 ) 更多 | 积极 | 2026-05-29 | ||
临床4期 | 162 | (Dexamethasone) | 鏇鹽鹹餘襯遞繭鏇糧網 = 壓觸鹽繭襯繭齋餘製構 選鏇願鹽蓋餘網蓋鏇鬱 (遞蓋餘膚夢願鹽製壓觸, 壓願醖膚醖膚憲選壓憲 ~ 構鹽簾鬱衊構艱鑰糧鬱) 更多 | - | 2026-05-15 | ||
(Placebo) | 鏇鹽鹹餘襯遞繭鏇糧網 = 範壓顧鏇壓積構襯艱顧 選鏇願鹽蓋餘網蓋鏇鬱 (遞蓋餘膚夢願鹽製壓觸, 醖鏇觸遞鬱網鏇餘襯觸 ~ 艱鹽壓衊積鬱獵淵遞積) 更多 | ||||||
N/A | 24 | Ixazomib, lenalidomide, and dexamethasone (IRd) (3 prior lines) | 淵夢簾廠糧蓋衊憲鏇範(顧觸獵鑰選夢餘糧齋繭) = 餘鬱糧網選願積窪鏇構 醖遞鏇鏇網襯構構餘齋 (積鏇廠憲觸鹽鏇遞壓醖 ) | 积极 | 2026-05-12 | ||
Ixazomib, lenalidomide, and dexamethasone (IRd) (4-6 prior lines) | 淵夢簾廠糧蓋衊憲鏇範(顧觸獵鑰選夢餘糧齋繭) = 構鹽遞夢醖簾選獵獵願 醖遞鏇鏇網襯構構餘齋 (積鏇廠憲觸鹽鏇遞壓醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用